Theralase Technologies Inc. (TLT) - Total Liabilities
Based on the latest financial reports, Theralase Technologies Inc. (TLT) has total liabilities worth CA$1.91 Million CAD (≈ $1.38 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TLT operating cash flow to assess how effectively this company generates cash.
Theralase Technologies Inc. - Total Liabilities Trend (2001–2024)
This chart illustrates how Theralase Technologies Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check Theralase Technologies Inc. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Theralase Technologies Inc. Competitors by Total Liabilities
The table below lists competitors of Theralase Technologies Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Monalisa
KO:012690
|
Korea | ₩15.67 Billion |
|
Flanigans Enterprises Inc
NYSE MKT:BDL
|
USA | $62.29 Million |
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
USA | $40.10 Million |
|
Eltek Ltd
NASDAQ:ELTK
|
USA | $19.60 Million |
|
Scilex Holding Company
NASDAQ:SCLX
|
USA | $455.60 Million |
|
Anson Resources Ltd
AU:ASN
|
Australia | AU$3.71 Million |
|
OneConstruction Group Limited Ordinary Shares
NASDAQ:ONEG
|
USA | $4.79 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Theralase Technologies Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TLT market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theralase Technologies Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theralase Technologies Inc. (2001–2024)
The table below shows the annual total liabilities of Theralase Technologies Inc. from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$1.18 Million ≈ $853.23K |
-13.99% |
| 2023-12-31 | CA$1.37 Million ≈ $992.02K |
+28.36% |
| 2022-12-31 | CA$1.07 Million ≈ $772.82K |
+22.12% |
| 2021-12-31 | CA$874.79K ≈ $632.81K |
+2.06% |
| 2020-12-31 | CA$857.13K ≈ $620.04K |
-46.92% |
| 2019-12-31 | CA$1.61 Million ≈ $1.17 Million |
-37.07% |
| 2018-12-31 | CA$2.57 Million ≈ $1.86 Million |
+100.90% |
| 2017-12-31 | CA$1.28 Million ≈ $923.86K |
+132.32% |
| 2016-12-31 | CA$549.74K ≈ $397.67K |
-30.03% |
| 2015-12-31 | CA$785.66K ≈ $568.34K |
+53.52% |
| 2014-12-31 | CA$511.75K ≈ $370.19K |
-44.43% |
| 2013-12-31 | CA$920.99K ≈ $666.23K |
-23.08% |
| 2012-12-31 | CA$1.20 Million ≈ $866.17K |
+25.29% |
| 2011-12-31 | CA$955.71K ≈ $691.35K |
+35.30% |
| 2010-12-31 | CA$706.35K ≈ $510.97K |
+0.35% |
| 2009-12-31 | CA$703.90K ≈ $509.19K |
-11.44% |
| 2008-12-31 | CA$794.79K ≈ $574.94K |
+137.16% |
| 2007-12-31 | CA$335.12K ≈ $242.42K |
+6.81% |
| 2006-12-31 | CA$313.74K ≈ $226.96K |
+97.34% |
| 2005-12-31 | CA$158.99K ≈ $115.01K |
-1.57% |
| 2004-12-31 | CA$161.52K ≈ $116.84K |
-25.13% |
| 2003-12-31 | CA$215.75K ≈ $156.07K |
+1912.38% |
| 2002-12-31 | CA$10.72K ≈ $7.76K |
+12.16% |
| 2001-12-31 | CA$9.56K ≈ $6.91K |
-- |
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, m… Read more